Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04704050 · ClinicalTrials.gov registry record · Phase 4
Effect of Dronedarone on Atrial Fibrosis Progression and Atrial Fibrillation Recurrence
A Phase 4 study, sponsored by Tulane University School of Medicine.
- Terminated
- Registry status
- Phase 4
- Development phase
- 22
- Enrollment target
NCT04704050: Clinical Trial Phase 4 study, sponsored by Tulane University School of Medicine.
NCT04704050 is a Phase 4 study that was terminated before completion, run by Tulane University School of Medicine. The registered enrollment target is 22 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04704050, a Phase 4 study, was terminated before completion, sponsored by Tulane University School of Medicine.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 22 participants
- Enrollment target
Study Summary
Patients who have undergone cardiac ablation will be randomized and blinded to one of two groups; one group will receive dronedarone while the other group will receive a placebo. The incidence of atrial fibrillation recurrence, as well as atrial fibrosis progression, will be analyzed between the two trial groups.
Primary Outcome
Investigators monitored subjects upon discharge, 24-48 hours after AF ablation. This was recorded by either the occurrence of a single positive atrial arrhythmias (AA) ECG reading on a 12-lead ECG, Holter monitor, obtained on the daily event strips from the Preventice monitoring device, or 30-day monitoring patch.
Interventions
- DRUG Placebo
- DRUG dronedarone 400 mg Oral Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2021-05-15 |
| Est. Completion | 2022-12-20 |
| Phase | Phase 4 |
Why NCT04704050 stopped before completion
NCT04704050 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04704050 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04704050 about?
NCT04704050 is a clinical study titled "Effect of Dronedarone on Atrial Fibrosis Progression and Atrial Fibrillation Recurrence". Patients who have undergone cardiac ablation will be randomized and blinded to one of two groups; one group will receive dronedarone while the other group will receive a placebo. The incidence of atrial fibrillation recurrence, as well as atrial fibrosis progression, will be analyzed between the two...
What is the current status of trial NCT04704050?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 22 participants. The study started on 2021-05-15. Estimated completion is 2022-12-20.
What interventions are being tested in trial NCT04704050?
The interventions under investigation include: Placebo (DRUG), dronedarone 400 mg Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT04704050?
This trial is sponsored by Tulane University School of Medicine, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04704050's enrollment target sits among peer trials
22 1731st of 2000 higher than 259 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI